News | August 28, 2012

ACR Says New Study Is Good News for Women With Dense Breasts

August 28, 2012 — According to the American College of Radiology (ACR), a paper by Gierach et al. in the Journal of the National Cancer Institute (which is not the National Cancer Institute's journal) says that, although they are at a small increased risk of developing breast cancer, women with dense breast tissue (a large percentage of fibrous and glandular tissues) are not at an increased risk of dying from breast cancer when compared to women with mostly fat in their breasts.

Concerns have been raised that because the ability of mammography to find cancers is somewhat reduced in women with dense breasts, they should be additionally screened with ultrasound or magnetic resonance imaging (MRI). Although it is true that supplemental screening can detect additional cancers that are not found by mammography, there are many more "false alarms" with such use compared to mammography. These include more follow-up studies and more biopsies for findings that are not cancerous. Furthermore, mammography is the only test that has been shown in randomized, controlled trials to actually save lives.

State legislatures have passed and continue to pass laws requiring radiologists to notify women that they have dense breast tissue. Some laws mention that women might want to participate in MRI and/or ultrasound screening because they have dense breasts. However, it is unknown if such screening can actually benefit them in terms of saving lives. It is important to remember that there are women who should have supplemental screening with MRI due to a high-risk status. These include women with a strong family history of breast cancer and others. Strategies other than supplemental screening can be employed to reduce breast cancer risk among high-risk women. Thus, women should speak with their doctors about their risk factors to fully explore available options.

Ultrasound and MRI were not used routinely for screening among the women who were studied in the Gierach study. Rather than requiring additional tests that may produce more false alarms, ACR says, the emphasis should be on supporting trials of MRI and ultrasound to determine whether or not using them for screening average risk women can further reduce the death rate when added to mammography. 

In this study, women who were “obese” with fatty breasts were at increased risk of dying from their breast cancers. This emphasizes the fact that having fatty breast tissue does not protect a woman from developing and dying of breast cancer. This paper reinforces the fact that all women, regardless of their breast density, should participate in annual mammography screening beginning at the age of 40.

For more information: www.mammographysaveslives.org

To read a rebuttal opinion from Are You Dense Inc., click here.

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

Feature | Breast Imaging | July 03, 2019 | By Greg Freiherr
Productivity and its enabler — efficiency — guided the display of products at the April...
Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine
Feature | Women's Health | July 03, 2019 | By Samir Parikh
Contrary to what many people believe,...

Image courtesy of GE Healthcare

Feature | Radiology Business | July 03, 2019 | By Jeffrey Hoffmeister, M.D.
Burnout in the medical profession is not uncommon, particularly as clinicians have become more overwhelmed by growing